章滨云:关于奥密克戎(Omicron)8个防控策略步骤

2022-04-16 章滨云 章滨云微博

国内学者章滨云在其微博上发文,针对Omicron疫情防控,提出防控8个步骤的建议。

慈毅医疗基金创始人章滨云在其微博上发文,针对Omicron疫情防控,提出防控8个步骤的建议。

微博的原文如下:

中国在新冠两年多的防控中,取得了疫情防控与经济发展兼顾的效果。在当下面对新冠Omicron的冲击下,中国疫情防控还是要坚持谨慎科学求实的原则,我们的国情是人口众多,各区域发展不平衡,医疗资源分布也不均衡,不能轻易下场,要充分考虑到新冠病毒疫情防控的复杂性、艰巨性、反复性,建议要组织医防、经济等各相关领域的专家充分研讨,三思方举步,百折不回头。

个人建议的Omicron防控策略步骤:

步骤1. 本次全国一盘棋,需不惜代价努力动态清零,因为我们的老人们和我们自己都没准备好,至少要在竭尽努力之下把疫情控制在比较低的规模;

步骤2. 在吉林、上海等地抗疫的同时,全国>60岁老人坚决打加强针疫苗,现在疫情低的省市必须尽快实行;从香港数据看,80岁以上老人,未接种病死率15%,二剂及以上降到2.95%(科兴)和1.51%(复必泰)。我们对国产疫苗要有信心。同时后续的疫苗升级研发或引进要继续;

步骤3. 准备好物资、医疗资源、思想舆论、组织;

步骤4. 把冠状病毒疾病在传染病防治法中的分类进行重新划分:(1)SARS、MERS依乙类传染病实行甲类传染病管理;(2)新冠病毒Alpha、Beta、Gamma、Delta、Lambda等毒株目前依乙类传染病实行甲类传染病管理,如出现新的特效药物后,按乙类传染病管理;(3)新冠病毒Omicron毒株,建议按丙类传染病(相当于流感)进行管理,列入监测;

步骤5· 轻症无症状(非本波疫情)查抗原阳性居家,高危人群轻症上5日辉瑞药并本土化制造大幅降价或授予专利,重症就医上中和抗体等综合诊治方案;同时要防止传染病救治资源挤占原先的急诊、危重症、慢病和开药等资源,造成医疗次生灾害;

步骤6. 根据疫情动态调整各地人口流动和上班、复学节奏,争取疫情速度相对可控,目标Omicron窗口期争取免疫

步骤7· 每年续打疫苗,应对新冠毒株继续突变,动态监测新冠病毒毒株的变化,如出现新的导致重症和死亡迅速上升毒株,要进一步调整公共卫生策略

步骤8. 继续研发或与各国公司合作生产特效药。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084724, encodeId=a6822084e24ae, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 26 08:40:58 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941960, encodeId=32191941960cf, content=<a href='/topic/show?id=dbf89e4006a' target=_blank style='color:#2F92EE;'>#防控策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97400, encryptionId=dbf89e4006a, topicName=防控策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 03 12:40:58 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858035, encodeId=9087185803556, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed May 11 08:40:58 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212155, encodeId=795f12121555f, content=有一定道理哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:25 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2023-01-26 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084724, encodeId=a6822084e24ae, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 26 08:40:58 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941960, encodeId=32191941960cf, content=<a href='/topic/show?id=dbf89e4006a' target=_blank style='color:#2F92EE;'>#防控策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97400, encryptionId=dbf89e4006a, topicName=防控策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 03 12:40:58 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858035, encodeId=9087185803556, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed May 11 08:40:58 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212155, encodeId=795f12121555f, content=有一定道理哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:25 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084724, encodeId=a6822084e24ae, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 26 08:40:58 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941960, encodeId=32191941960cf, content=<a href='/topic/show?id=dbf89e4006a' target=_blank style='color:#2F92EE;'>#防控策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97400, encryptionId=dbf89e4006a, topicName=防控策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 03 12:40:58 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858035, encodeId=9087185803556, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed May 11 08:40:58 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212155, encodeId=795f12121555f, content=有一定道理哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:25 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-05-11 jiafufeng@yaho
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084724, encodeId=a6822084e24ae, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 26 08:40:58 CST 2023, time=2023-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941960, encodeId=32191941960cf, content=<a href='/topic/show?id=dbf89e4006a' target=_blank style='color:#2F92EE;'>#防控策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97400, encryptionId=dbf89e4006a, topicName=防控策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 03 12:40:58 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858035, encodeId=9087185803556, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed May 11 08:40:58 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212155, encodeId=795f12121555f, content=有一定道理哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon Apr 18 12:06:25 CST 2022, time=2022-04-18, status=1, ipAttribution=)]
    2022-04-18 赛华佗

    有一定道理哦

    0

相关资讯

中国台湾省新冠病例激增,调整了哪些政策,如何应对?

根据中国台湾流行疫情指挥中心统计,多达99%确诊病例都是轻症或无症状个案,且新北市今天宣布启动居家照护,指挥中心今天下午在疫情记者会中宣布调整新冠肺炎确定病例轻重症分流收治条件,以强化医疗应变量能。

31省区市4月14日新增本土病例“3472+20694”例(2022.04.15)

4月14日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例3486例。其中境外输入病例14例(福建6例,广西3例,广东2例,四川2例,北京1例),含3例由无症状感染

2022年4月16日简报:日韩先后降低新冠的传染病等级,逐步取消防控隔离措施;香港单日新增仅946例,台湾超千例;印度新增723例

截至北京时间2022年4月16日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过5亿352万例,新增657,035例,达到503,527,71

2022年4月14日简报:上海昨日新增3200+19872例;日本将新冠病毒划分为普通流感病毒一类;苏州新增阳性感染者16例;中国台湾省新增874例本土新冠肺炎病例,再创新高

截至北京时间2022年4月15日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过5亿280万例,新增913,843例,达到502,809,06

上海4月14日新增3200例本土确诊病例,新增19872例本土无症状感染者(2022.04.15)

2022年4月14日0—24时,上海新增本土新冠肺炎确诊病例3200例和无症状感染者19872例,其中307例确诊病例为此前无症状感染者转归,2547例确诊病例和19494例无症状感染者在

近期国内新冠病毒感染人数,重症人数,死亡情况大汇总(从2022.03.18到2022.04.15)

国家卫健委每天都通报国内新冠病毒感染情况,包括确诊病例,无症状感染病例,以及重症病例,死亡病例,当前现有确诊病例等数量。